GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guobang Pharma Ltd (SHSE:605507) » Definitions » Price-to-Owner-Earnings

Guobang Pharma (SHSE:605507) Price-to-Owner-Earnings : 41.49 (As of Jun. 01, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Guobang Pharma Price-to-Owner-Earnings?

As of today (2025-06-01), Guobang Pharma's share price is ¥20.33. Guobang Pharma's Owner Earnings per Share (TTM) ended in Mar. 2025 was ¥0.49. It's Price-to-Owner-Earnings for today is 41.49.


The historical rank and industry rank for Guobang Pharma's Price-to-Owner-Earnings or its related term are showing as below:

SHSE:605507' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 38.03   Med: 64.63   Max: 190.71
Current: 41.33

During the past 8 years, the highest Price-to-Owner-Earnings of Guobang Pharma was 190.71. The lowest was 38.03. And the median was 64.63.


SHSE:605507's Price-to-Owner-Earnings is ranked worse than
69.64% of 448 companies
in the Drug Manufacturers industry
Industry Median: 25.175 vs SHSE:605507: 41.33

As of today (2025-06-01), Guobang Pharma's share price is ¥20.33. Guobang Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥1.42. Therefore, Guobang Pharma's PE Ratio (TTM) for today is 14.32.

As of today (2025-06-01), Guobang Pharma's share price is ¥20.33. Guobang Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was ¥1.45. Therefore, Guobang Pharma's PE Ratio without NRI for today is 14.04.

During the past 8 years, Guobang Pharma's highest PE Ratio without NRI was 24.32. The lowest was 12.49. And the median was 15.01.


Guobang Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Guobang Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guobang Pharma Price-to-Owner-Earnings Chart

Guobang Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - 47.89

Guobang Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.88 78.17 64.58 47.89 41.48

Competitive Comparison of Guobang Pharma's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guobang Pharma's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Guobang Pharma's Price-to-Owner-Earnings falls into.


;
;

Guobang Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Guobang Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=20.33/0.49
=41.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guobang Pharma  (SHSE:605507) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Guobang Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Guobang Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Guobang Pharma Business Description

Traded in Other Exchanges
N/A
Address
No. 60, Xingmei Avenue, Provincial High-tech Industrial Park, Zhejiang Province, Xinchang, CHN, 312500
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.

Guobang Pharma Headlines

No Headlines